Introduction
============

All-*trans* retinoic acid (ATRA) exerts essential roles in reproduction, embryogenesis, cell proliferation, differentiation and apoptosis ([@b1-ijmm-43-04-1789],[@b2-ijmm-43-04-1789]). ATRA also regulates skin function and is widely used for the treatment of skin diseases such as acne, psoriasis, ichthyosis and skin cancer ([@b3-ijmm-43-04-1789]-[@b5-ijmm-43-04-1789]), but its clinical application is limited by adverse skin reactions, including erythema, scaling, dryness, desquamation and vessel dilation. These reactions are potentially associated with epidermal barrier dysfunction ([@b6-ijmm-43-04-1789]), but the mechanisms are largely unknown.

Tight junctions (TJs) in epithelial and endothelial tissues have been well studied, and a previous study suggested that the TJs of the stratum granulosum (SG) are responsible for the protective function of epithelial tissues ([@b7-ijmm-43-04-1789]). TJs consist of transmembrane Claudins, adherent junction (AJ) molecules, occludin, plaque proteins (e.g. zonula occludens-1, -2 and -3, and multiple PDZ domain protein), and cell polarity complex proteins \[e.g. the protein kinase C ι-type/partitioning defective 3 homolog (Par3)/Par6 complex\] ([@b8-ijmm-43-04-1789]). Claudins contain two extracellular loops (cytoplasmic C- and N-terminal) and four transmembrane domains ([@b9-ijmm-43-04-1789],[@b10-ijmm-43-04-1789]). Claudins-1, -2, -4 and -6 are essential for TJ formation and are involved in the barrier to paracellular transport ([@b9-ijmm-43-04-1789],[@b11-ijmm-43-04-1789]-[@b14-ijmm-43-04-1789]). The roles of Claudins in barrier function have been addressed in epithelial cell cultures and Claudin-knockout/transgenic mice ([@b15-ijmm-43-04-1789],[@b16-ijmm-43-04-1789]). Claudin-1 and -4 are concentrated in TJs ([@b17-ijmm-43-04-1789]). Continuous Claudin-based TJs are present in the epidermis and these particular TJs are crucial for the barrier function of mammalian skin ([@b17-ijmm-43-04-1789]). In addition, Claudin-1 and -4 are involved in the pathogenesis of skin lesions ([@b18-ijmm-43-04-1789]-[@b20-ijmm-43-04-1789]). How Claudin-1 and -4 are regulated in response to ATRA is largely unknown.

To understand the molecular basis of ATRA-induced barrier dysfunction, a gene expression array was used to observe the differential gene expression in mouse skin and HaCaT cells following treatment with ATRA. Using a mouse model and a gene expression array, it was demonstrated that ATRA does, in fact, alter the structure of TJs in mouse skin. Therefore, the hypothesis was that Claudins possibly exert an essential role in barrier dysfunction during ATRA-induced skin irritation. The present study aimed to investigate the molecular mechanisms of barrier dysfunction during ATRA-induced skin irritation.

Materials and methods
=====================

Animals
-------

Male BALB/c mice (n=32; 8 weeks of age; weight, \~25 g) were obtained from Xi'an Jiaotong University Animal Center (Xi'an, China). The mice were fed standard chow and had access to water *ad libitum*, and were caged in a controlled environment (12 h light/dark cycle; temperature, 20-25°C; humidity, 45-55%). The mice were acclimatized for 3 days prior to any experiments. All experimental procedures were performed in accordance with the 'Principles of Laboratory Animal Care' (NIH) and with the approval of the laboratory animal care committee of Xi'an Jiaotong University (no. XJTULAC2017-733).

Animal treatment
----------------

The skin on the backs of the mice was shaved using an electric shaver. The mice were divided into two group: i) Treated with topical 0.1% ATRA cream (Chongqing Winbond Pharmaceutical Co., Ltd., Chongqing, China) twice a day; and ii) treated with an oil/water cream (vehicle control) twice a day. The Psoriasis Area and Severity Index (PASI) scoring system was used to assess the severity of inflammation on the back skin of the mice ([@b21-ijmm-43-04-1789]). The PASI is widely used in clinical practice. Erythema, scales and thickening are scored as follows: 0, absent; 1, slight; 2, mild; 3, obvious; and 4, very obvious. The sum of the scores of these three factors is an indicator of the severity of inflammation (score of 0-12).

After 5 days of treatment, the mice were anesthetized using pentobarbital at 50 mg/kg. The skin from the backs of the mice, including the dermis and subcutaneous tissues, was removed. The skin was washed with pre-cooled PBS, excess fat was removed, and the specimens were placed in liquid nitrogen for RNA extraction. Subsequently, the mice were sacrificed by cervical dislocation.

Histological and ultrastructural analysis
-----------------------------------------

ATRA-treated and untreated mouse dorsal skin specimens (1×1.5 cm) were fixed in 4% paraformaldehyde for 24 h at 4°C, dehydrated and embedded in paraffin. The samples were sectioned at 7 *µ*m and stained with hematoxylin for 5 min and eosin for 2 min at room temperature. The epidermal thickness, parakeratosis, spongiosis and degree of inflammation were evaluated. Spongiosis (presence of widened intracellular spaces between epidermal keratinocytes) and inflammation were evaluated on a scale of 0-4. Epidermal thickness and spongy edema were measured using the built-in measurement tool in the software ndp.view2 (Hamamatsu Photonics K.K., Hamamatsu, Japan; <https://www.hamamatsu.com/jp/en/product/type/U12388-01.html>; version 2.7). The expanded capillaries were counted at high magnification (×200) in 10 randomly selected fields under an Olympus BX51 light microscope equipped with a DP70 digital camera (Olympus Corporation, Tokyo, Japan). Incomplete keratinization was assessed as present or absent ([@b22-ijmm-43-04-1789]).

The specimens were cut into 1-cm blocks and dipped in ice-cold sodium cacodylate buffer solution containing 2.5% glutaraldehyde at 4°C for 24 h. The blocks were washed three times and treated with 1% osmium tetroxide at 4°C for 1 h. The samples were dehydrated using an ethanol series and embedded in Epon 812. Ultra-thin sections were stained with lead citrate for 10 min and uranyl acetate for 30 min at room temperature. Ultrastructural changes were observed by transmission electron microscopy (TEM) using a H7650 microscope (Hitachi, Ltd., Tokyo, Japan).

Cell culture and treatment
--------------------------

HaCaT cells (immortalized keratinocytes) were obtained from the Fourth Military Medical University (Shan'xi, China) and grown in RPMI-1640 (GE Healthcare, Chicago, IL, USA) with 10% fetal bovine serum (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin (GE Healthcare). Short tandem repeat profiling was performed by Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China) to validate the cell line. The cells were subcultured following dissociation with 0.25% trypsin/0.05% EDTA (1:1) and passaged at a ratio of 1:4 every 3 days.

HaCaT cells (5,000 cells/well) were incubated in 96-well plates for 48 h and treated by different concentrations (0.1, 0.5, 1, 5 and 10 *µ*M) of ATRA at 37°C for a further 36 h. A volume of 20 *µ*l MTT solution (5 mg/ml) was added to each well and the culture continued for 4 h. Subsequently, the medium was removed, and 150ul dimethyl sulfoxide (DMSO) was added to each well. The light absorption value of each well was measured at optical density 490 nm (570 nm) with a micro-plate reader. Following determination of the half-maximal inhibitory concentration using different concentrations of ATRA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), HaCaT cells were incubated with or without 1 *µ*M ATRA for 36 h at 37°C, which was chosen for use in the subsequent experiments. Stock solutions of ATRA (0.01 M) were prepared in DMSO, stored in the dark at −20°C, and further diluted with RPMI-1640. The concentration of DMSO was 1‰.

Microarray analysis
-------------------

Microarray analysis was used primarily to identify candidates that were later confirmed via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and/or immunohistochemistry. The gene expression profiles in the skin of mice and in HaCaT cells treated or untreated with ATRA were compared using NimbleGen Gene Expression analysis (Nimblegen Systems Inc., Madison, WI, USA). The ds-cDNA samples were washed and labeled according to the Nimblegen Gene Expression Analysis protocol (Nimblegen Systems Inc.). A NanoDrop ND-1000 was used to quantify the cDNA following purification. Cy3 labeling was conducted using the NimbleGen One-Color DNA labeling kit (NimbleGen Systems, Inc.), according to the manufacturer's protocol. Subsequently, 100 U Klenow fragment (New England Biolabs, Inc., Ipswich, MA, USA) and 100 pmol deoxynucleoside triphosphates were added and incubated at 37°C for 2 h. One-tenth volume of 0.5 M EDTA was added to stop the reaction. The labeled ds-cDNA was purified using isopropanol/ethanol precipitation. The microarrays were immersed in the NimbleGen hybridization buffer/hybridization component A, which was supplemented with 4 *µ*g ds-cDNA with Cy3 labeling. The reaction system was kept in a hybridization chamber (Nimblegen Systems, Inc.) at 42°C for 4 h. The NimbleGen Wash Buffer kit (Nimblegen Systems, Inc.) was used to wash the microarrays in an environment without ozone. The Axon GenePix 4000B microarray scanner was used to scan the microarrays.

RT-qPCR
-------

The RNAeasy Midi kit (Qiagen AB, Sollentuna, Sweden) was used to isolate the total mRNA, according to the manufacturer's protocol. RNA (1 *µ*g) was added in a 20-*µ*l reaction system (PrimeScript RT Reagent Kit; Takara, Otsu, Japan) at 37°C for 15 min and 85°C for 5 sec for cDNA synthesis. The SYBR Premix Ex Taq II amplification kit (Perfect Real Time; Takara Biotechnology Co., Ltd., Dalian, China) was used for qPCR on a Bio-Rad IQ5 System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The conditions were: i) 95°C denaturation for 10 min; and ii) 40 cycles at 95°C for 10 sec and 60°C for 30 sec. The primers are listed in [Table I](#tI-ijmm-43-04-1789){ref-type="table"}. β-actin was used for normalization. The results were analyzed using the IQ5 software (version 2.5). Gene expression levels were calculated using the 2^−ΔΔCq^ method ([@b23-ijmm-43-04-1789]).

Western blotting
----------------

ATRA-treated and untreated HaCaT cells were lysed in radioimmunoprecipitation assay buffer \[150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.5% deoxycholate, 0.1% SDS, 1% Nonidet P-40 and protease inhibitor cocktail; Sigma-Aldrich; Merck KGaA\] at 4°C for 1 h. Protein concentration was measured using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of proteins (30 *µ*g) were separated on 12% SDS-PAGE gels and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). TBS buffer containing Tween-20 (TBST) and 5% non-fat milk was used to block non-specific binding at room temperature for 2 h. Following blocking, primary antibodies were incubated overnight at 4°C: Rabbit anti-human Claudin-1 (cat. no. 13050-1-AP; ProteinTech Group, Inc., Chicago, IL, USA; 1:200), goat anti-human Claudin-4 (cat. no. 17664; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; 1:200) and mouse anti-human β-actin (cat. no. 47778; Santa Cruz Biotechnology, Inc.; 1:1,000). The membranes were washed three times with TBST for 5 min. Horseradish peroxidase (HRP)-conjugated Affinipure Rabbit Anti-Goat IgG (H+L) (cat. no. SA00001-2; ProteinTech Group, Inc.; 1:3,000), HRP-conjugated Affinipure Goat Anti-Mouse IgG (H+L) (cat. no. SA00001-1; ProteinTech Group, Inc.; 1:3,000) and HRP-conjugated Affinipure Donkey Anti-Goat IgG (H+L) (cat. no. SA00001-3; ProteinTech Group, Inc.; 1:4,000) were incubated for 1 h at 37°C prior to visualization with enhanced chemiluminescence (Amersham; GE Healthcare). Densitometry was used to quantify the signal intensities using Quantity One 4.5 software (Bio-Rad Laboratories, Inc.). All measurements were performed in triplicates from three independent experiments.

Immunofluorescence
------------------

HaCaT cells and cryostat sections (4 *µ*m) of skin from ATRA-treated and untreated mice were fixed in ice-cold 4% paraformaldehyde in PBS for 30 min. Non-specific binding was blocked with 10% normal goat serum (OriGene Technologies, Inc., Beijing, China) for 20 min at 37°C. Goat anti-human Claudin-4 (1:50) and rabbit anti-human Claudin-1 antibodies (1:50) were incubated overnight at 4°C. PBS was used as a negative control. The sections were washed twice for 5 min in PBS. Alexa Fluor 594-labeled secondary antibodies (cat. nos. A32758 and A32740; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; 1:200) were incubated for 1 h at room temperature and revealed using DAPI (1:5,000 in PBS) for 2 min at room temperature. A laser scanning confocal microscope (LSM510; Zeiss AG, Oberkochen, Germany) was used to capture images of the cells (×200 magnification).

Statistical analysis
--------------------

All statistical analyses were conducted using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation. All measurements were performed in triplicate from three independent experiments. The distribution was tested for normality using the Kolmogorov-Smirnov test. Statistical significance was evaluated by independent sample t-test for normally distributed data and using the Mann-Whitney U test for non-normally distributed data. P\<0.05 was considered to indicate a statistically significant difference.

For the microarray data, the NimbleScan software (version 2.5; NimbleGen Systems, Inc.) was used to conduct grid alignment and analyze the expression profiles. The Robust Multichip Average (RMA) algorithm and quantile normalization in NimbleScan software were applied to the normalized expression data. The gene levels were inputted into the Agilent GeneSpring software (version 12.0; Agilent Technologies, Inc., Santa Clara, CA, USA). Fold-change filtering was applied for the identification of genes with differential expression levels. The threshold was set at-fold-change ≥2.0. The Agilent GeneSpring GX software (version 12.0; Agilent Technologies, Inc.) was used to conduct hierarchical clustering. The roles of the differentially expressed genes were determined using Gene Ontology (GO; [www.geneontology.org](http://www.geneontology.org)) and pathway analyses (<https://www.genome.jp/kegg>) conducted on the basis of the standard enrichment computation method, and using Fisher's exact test to determine whether the amount of overlaps between the GO annotation list and the list of differentially expressed genes was significant. P≤0.05 indicated that the GO term enrichment was statistically significant.

Results
=======

Topical ATRA induces histological alterations in the skin of treated mice
-------------------------------------------------------------------------

After 5 days of treatment, no marked alterations were detected in the control skin. Circumscribed erythema occurred after 3 days of ATRA application (n=6), with fine flat scales covering the surface of the erythema that peaked at 5 days ([Fig. 1](#f1-ijmm-43-04-1789){ref-type="fig"}). Hematoxylin and eosin staining of ATRA-treated skin demonstrated crust, focal parakeratosis, hyperproliferation and intercellular edema of the stratum spinosum ([Fig. 2A](#f2-ijmm-43-04-1789){ref-type="fig"}). In the ATRA-treated dermis, large amounts of inflammatory cell infiltration and capillary dilation were observed ([Fig. 2A](#f2-ijmm-43-04-1789){ref-type="fig"}). Epidermal thickness was 2.5 times higher following ATRA intervention compared with that of the control group (P\<0.0001), in addition to increases in parakeratosis (P\<0.001) and spongiosis (P\<0.002). In the dermis, perivascular lymphocytic infiltration (P\<0.002) and telangiectasia (P\<0.002) were observed in the dermal papilla and in the superficial layer ([Fig. 2B](#f2-ijmm-43-04-1789){ref-type="fig"}).

ATRA treatment causes ultrastructural abnormalities in the epidermis
--------------------------------------------------------------------

Compared with control skin, keratohyalin granules were decreased in number in the SG (n=3; [Fig. 3A](#f3-ijmm-43-04-1789){ref-type="fig"}). TEM also demonstrated that the keratinocyte cytoskeleton was damaged by ATRA and that the cytoskeletal network disappeared in the local upper stratum corneum ([Fig. 3A](#f3-ijmm-43-04-1789){ref-type="fig"}). In the upper stratum corneum, multiple lipid droplets were observed in the cytoplasm of corneocytes in the ATRA-treated skin ([Fig. 3B](#f3-ijmm-43-04-1789){ref-type="fig"}). In the epidermis of ATRA-treated skin, TEM revealed a disordered arrangement of stratum spinosum cells, in addition to the appearance of significantly larger nucleoli and wider intercellular spaces ([Fig. 3B](#f3-ijmm-43-04-1789){ref-type="fig"}). Desmosomes were decreased and disordered in ATRA-treated skin ([Fig. 3C](#f3-ijmm-43-04-1789){ref-type="fig"}). Quantitative analysis of keratohyalin granules, lipid droplets and desmosomes is presented in [Fig. 3D](#f3-ijmm-43-04-1789){ref-type="fig"}.

Gene expression profiling reveals dysregulation of epidermal barrier-associated genes in the mouse epidermis and HaCaT cells treated with ATRA
----------------------------------------------------------------------------------------------------------------------------------------------

With the aim of improving the understanding of the molecular mechanisms of ATRA-induced barrier dysfunction, gene expression array analysis (n=1) was used to identify candidate genes for barrier function in the mouse skin and HaCaT cells. There were 897 upregulated and 1,087 downregulated genes following treatment with ATRA in the mouse epidermis. Similarly, there were 1,220 upregulated and 905 downregulated genes following treatment with ATRA in HaCaT cells. The genes involved in epidermal barrier function were revealed by gene expression analyses and are presented in [Tables II](#tII-ijmm-43-04-1789){ref-type="table"}--[](#tIII-ijmm-43-04-1789){ref-type="table"}[](#tIV-ijmm-43-04-1789){ref-type="table"}[V](#tV-ijmm-43-04-1789){ref-type="table"}. The downregulated epidermal barrier-associated genes following treatment with ATRA in the mouse skin included genes involved in 'cornified envelope components', 'intermediate filament', 'lipid metabolic process', 'gap junction', 'tight junction' and 'desmosome' ([Table II](#tII-ijmm-43-04-1789){ref-type="table"}). The upregulated epidermal barrier-associated genes following treatment with ATRA in mouse skin included genes involved in 'cornified envelope components', 'serine protease and protease inhibitors', 'lipid metabolic process', 'tight junction' and 'transcriptional factors' ([Table III](#tIII-ijmm-43-04-1789){ref-type="table"}). The downregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in 'intermediate filament', 'proteases and protease inhibitors' and 'tight junction' ([Table IV](#tIV-ijmm-43-04-1789){ref-type="table"}). The upregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in 'intermediate filament', 'proteases and protease inhibitors' and 'tight junction' ([Table V](#tV-ijmm-43-04-1789){ref-type="table"}).

The pathway analyses demonstrated that differentially expressed genes were significantly associated with AJs, TJs and focal adhesion in ATRA-treated epidermal tissues. The top ten pathways of up- and downregulated differentially expressed genes are presented in [Fig. 4A and B](#f4-ijmm-43-04-1789){ref-type="fig"}, respectively. The top ten three GO-fold enrichment of differentially expressed genes revealed significant downregulation of epidermal barrier function-associated processes, including 'regulation of keratinocyte differentiation', 'keratin filament' and 'gap junction' channel activity ([Fig. 4C-H](#f4-ijmm-43-04-1789){ref-type="fig"}). In ATRA-treated epidermal tissues, a series of dysregulated genes associated with the epidermal differentiation complex (EDC) were observed, which included small proline-rich region proteins (SPRRs), filaggrin (FLG), loricrin (LOR) and the S100 gene family. These proteins are essential for the formation of the cell envelope during terminal differentiation. A number of these genes were members of the SPRR family: *SPRR4* (−2.67-fold), *SPRR2J* (+2.38-fold) and *SPRR2G* (+3.57-fold). The remainder were part of the S100 gene family: *S100A8* (+3.31-fold) *S100A9* (+3.81-fold) and *FLG* (−2.13-fold) ([Tables II](#tII-ijmm-43-04-1789){ref-type="table"} and [III](#tIII-ijmm-43-04-1789){ref-type="table"}). During keratinocyte differentiation, the late cornified envelope protein (LCE) was induced and had similar functions to the functions of the SPRR family (cross-linking proteins) in the CE. *LCE1M* (6.64-fold) was downregulated, while *LCE3C* (5.35-fold) and *LCE3B* (3.17-fold) were upregulated ([Tables II](#tII-ijmm-43-04-1789){ref-type="table"} and [III](#tIII-ijmm-43-04-1789){ref-type="table"}). Nevertheless, no notable abnormalities were observed in the above genes in HaCaT cells. In ATRA-treated epidermal tissues and HaCaT cells, marked dysregulation of numerous keratins and keratin-associated proteins was observed, suggesting abnormal terminal differentiation of keratinocytes upon ATRA treatment. Serine proteases and serine protease inhibitors are involved in the differentiation of keratinocytes and desquamation ([@b24-ijmm-43-04-1789]). In ATRA-treated epidermal tissues and HaCaT cells, the differential expression of serine proteases and serine protease inhibitors was observed. Among them, it was observed that KLK6 and KLK10 were consistently expressed in the mouse chip and HaCaT cells, and all of them were upregulated.

Genes encoding enzymes associated with lipid metabolism were demonstrated to be induced by ATRA in the mouse epidermis. Compared with the cells, the mice exhibited significant downregulation of a subset of enzymes associated with ceramide, free fatty acids and phospholipid synthesis: i) Sphingomyelin phosphodiesterase 3 (*SMPD3*; -2.15-fold) and sphingomyelin phosphodiesterase 2 (*SMPD2*, -2.10-folds), which catalyze the conversion of sphingolipids to ceramides; ii) epidermal ceramide synthase 5 (*LASS5/Cers5*; -2.82-fold), which catalyzes the synthesis of ceramides; iii) lysophospholipase II (*LYPLA*; -2.00-fold), phospholipase A2 group IIE2 (*PLA2G2E*; -2.60-fold), and phospholipase C eta 2 (*PLCH2*; -2.13-fold), which catalyze free fatty acid formation from phospholipids; and iv) 1-acylglycerol-3-phosphate O-acyltransferase 4 (*AGPAT4*; -3.81-fold) and 1-acylglyc-erol-3-phosphate O-acyltransferase 5 (*AGPAT5*; -3.17-fold), which catalyze the acylation of lysophosphatidic acid into phosphatidic acid. The latter is the primary precursor of all types of glycerolipids. Furthermore, arachidonate lipoxygenase (*ALOX12E*; a member of the epidermis-type LOX family that catalyzes the conversion of polyunsaturated fatty acids into oxygenated products) was downregulated by ATRA. Conversely, the present results also demonstrated upregulation of different isoforms of the aforementioned enzymes ([Table III](#tIII-ijmm-43-04-1789){ref-type="table"}).

The dysregulation of numerous cell-cell junction-associated genes was observed in ATRA-treated mouse skin. Among these genes were components of TJs (*TJAP1*, *MPP7*, *MARVELD2* and *CLDN2*), gap junctions (*GJA, GJA* and *GJB4*) and desmosomes (*DSG2*). Compared with the mouse skin specimens, only the TJ protein molecules Claudin-4 and occludin were upregulated in the cells.

ATRA treatment alters the expression and localization of TJs in HaCaT cells
---------------------------------------------------------------------------

In ATRA-treated cells, *CLDN1* was downregulated 0.66-fold, while *CLDN4*, *TJP3* and *GJB4* were upregulated 1.82-, 3.63- and 1.92-fold ([Fig. 5A](#f5-ijmm-43-04-1789){ref-type="fig"}). In mice treated with ATRA, *CLDN1* (0.8-fold) and *FLG* (0.61-fold) were downregulated, while *CLDN4* (1.47-fold) and *CLDN2* (2.49-fold) were upregulated ([Fig. 5B](#f5-ijmm-43-04-1789){ref-type="fig"}). Western blot analysis of CLDN4 and CLDN1 revealed similar results to those of the RT-qPCR ([Fig. 5C](#f5-ijmm-43-04-1789){ref-type="fig"}).

Immunofluorescence revealed that the intensity of Claudin-1 was not only reduced at the cell-cell contact areas, but also appeared to be discontinuous along the cell membranes of HaCaT cells treated with ATRA ([Fig. 6](#f6-ijmm-43-04-1789){ref-type="fig"}). However, Claudin-4 staining was slightly increased and displayed a string-like localization pattern ([Fig. 6](#f6-ijmm-43-04-1789){ref-type="fig"}).

ATRA alters the expression and localization of TJs in mouse epidermis
---------------------------------------------------------------------

A marked reduction in the staining intensity and localization of Claudin-1 in the upper epidermal layer of skin treated with ATRA was discovered compared with control skin (n=3; [Fig. 7](#f7-ijmm-43-04-1789){ref-type="fig"}). By contrast, Claudin-4 staining was stronger in the ATRA-treated skin compared with control skin ([Fig. 7](#f7-ijmm-43-04-1789){ref-type="fig"}).

Discussion
==========

In the present study, the ATRA-associated dermatitis animal model presented erythema, scaling and dryness of the treated skin, similar to the irritation observed in ATRA-treated human skin ([@b25-ijmm-43-04-1789],[@b26-ijmm-43-04-1789]), indicating that this animal model is a useful tool to evaluate the effectiveness and side effects of ATRA. Furthermore, treatment with ATRA altered the normal morphology and ultrastructure of the mouse epidermis. Microarray analysis was used, primarily to identify candidates that were later confirmed via RT-qPCR and/or immunohistochemistry.

In the mouse model of ATRA-stimulated dermatitis, the epidermis of the mice exhibited obvious scales, while histopathology revealed parakeratosis of the epidermis, suggesting that the epidermal differentiation was abnormal, and that the abnormal differentiation of keratinocytes led to an epidermal keratinization envelope. In the mouse gene expression profiles, it was observed that the majority of alterations occurred among EDC genes, including *FLG*, *SPRR4*, *SPRR2J*, *SPRR2G*, *LCE3C*, *LCE3B*, *LCE1M*, *S100A8* and *S100A9*. The proteins encoded by those genes, together with LOR, involucrin, trichohyalin and hornerin, are associated with CE generation via crosslinking of insoluble membranous proteins ([@b27-ijmm-43-04-1789]). Keratinized proteins act as markers of differentiation in the epidermis. In the mice and cells, the abnormal expression of keratins, including *KRT15*, *KRT17* and *KRT14*, and keratin-associated proteins, including *KRT33A*, *KRT33A* and *KRTAP1-3*, was widely observed, further confirming the abnormal terminal differentiation in the epidermis following ATRA treatment.

Proteases, together with their inhibitors and targets, serve an essential role in desquamation ([@b24-ijmm-43-04-1789]). In the ATRA-treated mouse epidermis and HaCaT cells, the upregulation of tissue kallikreins (*KLK6*, *KLK10*, *KLK12* and *KLK14*) and protease inhibitors (*SERPINE 1* and *SERPINE 2*) was demonstrated. It is noteworthy that KLK6 and KLK10 were upregulated in mice and cells following ATRA treatment, which may be closely associated with the appearance of scales on the mouse skin. Furthermore, alterations in the balance between proteases and protease inhibitors in the skin lead to inflammatory reactions, which causes itching, scaling, redness and other typical clinical symptoms ([@b28-ijmm-43-04-1789]).

Morphologically, the appearance of profilaggrin is consistent with the formation of keratohyalin granules. The newly-synthesized profilaggrin accumulates in keratohyalin granules with high phosphoric acid and histidine following phosphorylation. The present study demonstrated that the number of keratohyalin granules decreased significantly following ATRA treatment. Therefore, it was speculated that decreases in the number of keratohyalin granules may affect the phosphorylation and accumulation of newly-synthesized profilaggrin, affecting the production of FLG. In addition, a number of factors that are important in controlling FLG expression have been described, such as transcription factors of the AP1 family (Jun and/or Fos), POU-domain proteins, transcription factor p63, and the peroxisome-proliferator-activated-receptor (PPAR) family ([@b29-ijmm-43-04-1789]). Aberrant profilaggrin processing has also been observed in 12R-lipoxygenase (12R-LOX)-deficient mice ([@b30-ijmm-43-04-1789]). In the present study, the gene chip results revealed that PPAR was upregulated and *ALOX12E* was downregulated following ATRA treatment. As expected, the gene chip analysis and RT-qPCR revealed that the expression of *FLG* was downregulated following ATRA treatment in the mouse skin, as supported by Sybert *et al* ([@b31-ijmm-43-04-1789]), who reported that patients with ichthyosis vulgaris displayed a reduction or absence of profilaggrin and FLG along with a morphological reduction in the amount of keratohyalin. Filaggrin is also involved in the production of primary natural moisturizing factors in the stratum corneum ([@b29-ijmm-43-04-1789]). Whether these alterations in expression may affect the expression of FLG and the specific regulatory mechanism requires further investigation.

Following ATRA treatment, alterations in the ultrastructure of the epidermis were observed under an electron microscope. The images revealed that there were numerous circular vacuolated structures in the stratum corneum, which were similar to the ultrastructure of lipid droplets. Ponec *et al* ([@b32-ijmm-43-04-1789]) studied the lipid and ultrastructure of reconstructed skin models by electron microscopy. Their results indicated that lipid droplets in keratinocytes appeared in all three skin models, but the extent of the lipid droplets varied. The structure of the lipid droplets in their images was consistent with the structure of lipid droplets observed under electron microscopy in the present study. It was also thought that the different levels of lipid droplets in keratinocytes were associated with the hyperproliferative state of reconstructed skin. On the other hand, the epidermal layers of the mice in the present study were increased following ATRA treatment, indicating that there was a degree of proliferation. Therefore, it was speculated that these structures may be lipid droplets. Nevertheless, this is a limitation of the present study.

The ATRA-treated mouse skin displayed a large number of lipid droplets in certain corneocytes \[similar in appearance to the droplets observed by Ponec *et al* ([@b32-ijmm-43-04-1789])\], suggesting that lipid metabolism was abnormal. Gene expression analysis of skin samples from ATRA-treated and control skin demonstrated significant induction of functional proteins associated ceramide, non-esterified fatty acids and phospholipid synthesis. The present study revealed down-regulation of *SMPD3*, *SMPD2* and *LASS5/Cers5*, which catalyze the synthesis of ceramides, suggesting decreased ceramide synthesis in ATRA-treated mice. Conversely, it was observed that ATRA also increased the expression of UDP-glucose ceramide glucosyltransferase (UGCG). Moreover, Amen *et al* ([@b33-ijmm-43-04-1789]) reported that mice with deficiencies in UGCG display an ichthyosis-like skin phenotype and impairment in the differentiation of keratinocytes, which is associated with delayed wound healing.

Mao-Qiang *et al* ([@b34-ijmm-43-04-1789]) demonstrated that inhibiting *PLA2* resulted in a defective extracellular lipid membrane and impaired homeostasis in the permeability barrier ([@b34-ijmm-43-04-1789]). In the present study, ATRA not only downregulated *PLA2G2E* and other phospholipases including *PLCH2,* but also upregulated *PLA2G4E*, *LYPLA* and *DEG*. Lu *et al* ([@b35-ijmm-43-04-1789]) demonstrated that the transcription levels of AGPAT-1, -2 and -3 were rapidly increased by ATRA. The present gene expression analysis of ATRA-treated skin revealed a marked reduction in the levels of *AGPAT4* and *AGPAT5*.

Previously, lipoxygenases (LOXs) were reported to exert essential roles in regulating epithelial proliferation and/or differentiation, maintaining the permeability barrier, skin inflammation and wound healing ([@b36-ijmm-43-04-1789]). In the present study, no marked alterations in the protein levels of *eLOX-3* and *12R-LOX* in ATRA-treated skin were detected, but ATRA-treatment significantly downregulated *ALOX12E*, which may have a role in regulating keratinocyte differentiation ([@b37-ijmm-43-04-1789]).

TEM analysis of the mouse skin revealed an increase in the intercellular space, suggesting that the keratinocytes of the mice may have had abnormalities in the TJs. TJs function as a paracellular barrier beneath the stratum corneum ([@b38-ijmm-43-04-1789]). In the present study, Claudin-1 was decreased, but Claudin-4 was increased following ATRA-treatment in HaCaT cells and the mouse epidermis. Claudin-1-knockout mice exhibit increased epidermal permeability, severe water loss and skin wrinkling, and succumb within 24 h after birth ([@b17-ijmm-43-04-1789]). Downregulation of Claudin-1 results in decreased transepithelial electrical resistance ([@b39-ijmm-43-04-1789]). In addition, patients with atopic dermatitis exhibit low levels of Claudin-1 expression ([@b40-ijmm-43-04-1789]). Nevertheless, a previous *in vitro* study of cultured keratinocytes uncovered barrier defects resulting from knocking down Claudin-4 ([@b41-ijmm-43-04-1789]). The present study revealed that the expression of Claudin-4 was increased following ATRA treatment in HaCaT cells and the mouse epidermis, as previously observed in the oral mucosa ([@b14-ijmm-43-04-1789]). Nevertheless, significant upregulation of Claudin-4 was observed in the non-lesional skin of patients with atopic dermatitis, which may indicate a compensatory response to disrupted barrier function caused by Claudin-1 downregulation that leads to the upregulation of other Claudins ([@b18-ijmm-43-04-1789],[@b42-ijmm-43-04-1789]). Therefore, downregulated Claudin-1 and the alteration of its localization in HaCaT cells and the mouse epidermis was likely responsible, at least in part, for the observed disruption of TJ barrier function following ATRA treatment.

It was observed that Claudin-2 mRNA was upregulated 2.5-fold. Telgenhoff *et al* ([@b43-ijmm-43-04-1789]) studied the regulation of Claudin-2 mRNA and protein expression by ATRA in human keratinocytes, and discovered that ATRA increases the expression of Claudin-2 in keratinocytes in a dose-dependent manner. In addition, Claudin-2 is highly expressed in the TJs of mouse renal proximal tubules, which possess a leaky epithelium whose unique permeability properties underlie their high rate of NaCl reabsorption ([@b43-ijmm-43-04-1789],[@b44-ijmm-43-04-1789]). On the other hand, the Cldn2-KO mice display a normal appearance, activity, growth and behavior, with no abnormalities in the epidermal barrier ([@b44-ijmm-43-04-1789]); therefore, it was not included in the present study as a candidate gene due to funding limitations, but it may be considered in future studies.

Notably, certain differences were observed between the *in vivo* and the *in vitro* experiments. The possible causes include the following: i) HaCaT cells are human-derived immortalized keratin-forming cells, while the skin tissues were derived from mice, thus the two are different in species; ii) cells growing *in vitro* and *in vivo* are not completely analogous; and iii) the doses of ATRA *in vivo* and *in vitro* were different. In addition, the present study is limited since it focused primarily on Claudin-1 and -4, and additional studies are required to assess the exact contribution to ATRA-induced dermatitis of all the identified differentially expressed genes. The microarray experiment would ideally have been performed in multiple samples, but research funding was very limited; thus, there was only one sample per group, which is a limitation. Nevertheless, the microarray experiment only provides an idea of the potential genes that may be examined in future studies. Subsequent experiments *in vivo* and *in vitro* will be performed to confirm the results.

In conclusion, the results suggest that ATRA disrupts the normal morphology and ultrastructure of the mouse epidermis and exerts an essential role in the function of the epidermal barrier. Gene expression analyses revealed numerous dysregulated genes associated with the synthesis/generation of transcription factors, protease inhibitors, proteases, junctional proteins, lipids, corneocytes and cornified envelopes. ATRA not only alters the expression of Claudin-1 and -4, but also alters their localization in HaCaT cells and the murine epidermis. ATRA exerts a dual effect on epidermal barrier genes: It downregulates the expression of Claudin-1 and upregulates the expression of Claudin-4. Claudin-4 upregulation may be a compensatory response for the disrupted barrier function caused by Claudin-1 downregulation.
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ATRA

:   all-*trans* retinoic acid

TEM

:   transmission electron microscopy

TJs

:   tight junctions

GO

:   Gene Ontology

DMSO

:   dimethyl sulfoxide

EDC

:   epidermal differentiation complex

SPRRs

:   small proline-rich region proteins

FLG

:   filaggrin

LOR

:   loricrin

![Effect of ATRA on morphological changes and PASI score on the back skin of mice. (A) After 5 days of treatment, no obvious alterations were detected in the control skin. Circumscribed erythema occurred after 3 days of ATRA application and gradually expanded, presenting as fine flat scales covering the surface of the erythema and peaking at 5 days. (B) The PASI scoring system was used to assess the severity of inflammation on the back skin of the mice. ^\*^P\<0.05, ^\*\*^P\<0.01 vs. respective control. PASI, Psoriasis Area and Severity Index; ATRA, all-*trans* retinoic acid.](IJMM-43-04-1789-g00){#f1-ijmm-43-04-1789}

![Effect of ATRA on histological changes in the mouse epidermis and quantitative analysis. (A) The mice were treated with topical 0.1% ATRA cream or oil/water cream (vehicle) twice a day. The mice were sacrificed after 5 days of ATRA treatment. The stratum corneum was impaired and the number of epidermal cell layers and epidermal thickness were increased in ATRA-treated mice. Parakeratosis (black arrows), intercellular edema (triangles), and dermal inflammatory cell infiltration (white arrows) were also observed. n=6 per group. Scale bar, 100 *µ*m. A representative image was selected from each group. (B) Quantitative analysis of epidermal cell layers, epidermal thickness, parakeratosis spongiosis, perivascular lymphocytic infiltration and telangiectasia. ATRA, all-*trans* retinoic acid.](IJMM-43-04-1789-g01){#f2-ijmm-43-04-1789}

![Effect of ATRA on ultrastructural alterations in the mouse epidermis. (A) The stratum corneum was impaired and the number of epidermal cell layers and epidermal thickness were increased. The number of KGs around granular cells were decreased (arrows). (B) There were multiple lipid droplets in the corneocytes (arrows). The volume of the spinous layer cells was increased, the nucleoli were significantly larger, and the intercellular space was widened (triangles). (C) Desmosomes were reduced in number and damaged (arrows). n=3/group. A representative image is presented for each group. (D) The numbers of KGs, lipid droplets and desmosomes were quantified. KC, keratinocyte; SC, stratum corneum; SG, stratum granulosum; D, desmosome; N, nucleus; KGs, keratinocyte granules; ATRA, all-*trans* retinoic acid.](IJMM-43-04-1789-g02){#f3-ijmm-43-04-1789}

![Top ten pathways of up- and downregulated genes. The bar plots indicate the top ten (A) down- and (B) upregulated enrichment score \[−log ^(P-value)^ 10\] values of the significantly enriched pathways (n=1 per group). The top ten (C) down- and (D) upregulated-fold enrichment \[(Count/Pop.Hits)/(List.Total/Pop.Total)\] values of the significant biological processes are presented. The bar plots indicated the top ten (E) down- and (F) upregulated-fold enrichment \[(Count/Pop.Hits)/(List.Total/Pop.Total)\] values of the significant cellular components. The top ten (G) down- and (H) upregulated-fold enrichment \[(Count/Pop.Hits)/(List.Total/Pop.Total)\] values of the significant molecular functions are presented. Count, the number of differentially expressed genes associated with the listed GOID; Pop.Hits, the number of background population genes associated with the listed GOID; List.Total, the total number of differentially expressed genes; and Pop.Total, the total number of background population genes. GO, Gene Ontology.](IJMM-43-04-1789-g03){#f4-ijmm-43-04-1789}

![mRNA and protein expression levels of CLDN1 and CLDN4 in immortalized keratinocyte HaCaT cells treated with ATRA. HaCaT cells were incubated with or without 1 *µ*M ATRA for 36 h. (A) In the cells, CLDN-4, TJP3 and JGB4 were upregulated, while CLDN1 was downregulated. (B) In mice, CLDN1 and FLG were downregulated, while CLDN4 and CLDN2 were upregulated. (C) CLDN1 and CLDN4 protein expression levels were determined by western blotting. β-actin was used as a loading control. Data are presented as the mean ± standard deviation from three independent experiments performed in triplicate (n=3). ^\*^P\<0.05 vs. respective vehicle group. CLDN, Claudin; ATRA, all-*trans* retinoic acid; TJP3, tight junction protein 3; GJB4, gap junction protein β4; FLG, filaggrin.](IJMM-43-04-1789-g04){#f5-ijmm-43-04-1789}

![Localization and expression of CLDN1 and CLDN4 in cultured HaCaT cells treated with ATRA. The localization of CLDN4 and CLDN1 (both red) was observed at the intercellular border in a string-like pattern in HaCaT cells treated with the vehicle. In ATRA-treated cells, CLDN4 immunofluorescence at the cell-cell contact sites appeared to be more intense compared with that in the vehicle group, while CLDN1 exhibited increased punctate localization in ATRA-treated cells. DAPI was used as a counterstain (blue). Scale bar, 20 *µ*m. CLDN, Claudin; ATRA, all-*trans* retinoic acid.](IJMM-43-04-1789-g05){#f6-ijmm-43-04-1789}

![Effect of ATRA on the localization and expression of CLDN1 and CLDN4 in mouse epidermal tissues. Following ATRA treatment, CLDN1 (red) was expressed at the cell-cell borders in the granular and spinous layers, but disappeared from the basal layers. CLDN4 (red) was expressed at the cell-cell borders in the granular layer and was enhanced in the upper spinous layer and granular layer following treatment with ATRA. DAPI was used as a counterstain (blue). Dotted lines indicate the basal layer. Scale bar, 20 *µ*m. n=3 per group. A representative image was selected from each group. CLDN, Claudin; ATRA, all-*trans* retinoic acid.](IJMM-43-04-1789-g06){#f7-ijmm-43-04-1789}

###### 

Primers for reverse transcription-quantitative polymerase chain reaction.

  Gene symbol                     Primers
  ------------------------------- ---------------------------------
  β-actin                         F-5′-AGCAGAGAATGGAAGAGTAAA-3′
  R-5′-ATGCTGCTTACATGTCTCGAT-3′   
  CLDN4                           F-5′-TATGGATGAACTGCGTGGTG-3′
  R-5′-GATGATGVTGATGATGACGAG-3′   
  CLDN1                           F-5′-GAAGTGTATGAAGTGCTTGG-3′
  R-5′-GGGTCATAGGGTCATAGAAT-3′    
  CLDN2                           F-5′-GTGAAGGCAGAGATGAGAAGAGG-3′
  R-5′-ATGGGATTTGGGCTTTTGG-3′     
  FLG                             F-5′-AGACTGGGAGGCAAGCTACAAC-3′
  R-5′-TGGTTTGGAGTGGGATTGCT-3′    

F, forward; R, reverse; CLDN, Claudin; FLG, filaggrin.

###### 

Downregulation of epidermal barrier-associated genes following treatment with all-*trans* retinoic acid in mouse skin (n=1 per group;-fold change \>2; P\<0.05).

  A, Cornified envelope components                                                                        
  ---------------------------------- ------------- ------------------------------------------------------ ---------------------
  AF510860                           FLG           Filagrin                                               2.13
  BC108980                           FOXN1         Forkhead box N1                                        2.42
  BC107019                           SPRR4         Small proline-rich protein 4                           2.67
  BC109181                           LCE1M         Late cornified envelope 1M                             6.64
  BC031486                           PPHLN1        Periphilin 1                                           2.40
  BC119192                           GPRC5D        Protein-coupled receptor, class C, group 5, member D   20.66
                                                                                                          
  **B, Intermediate filament**                                                                            
                                                                                                          
  GenBank accession no.              Gene name     Gene full name                                         Fold downregulation
                                                                                                          
  BC003472                           KRT23         Keratin 23                                             2.67
  BC129847                           KRT24         Keratin 24                                             2.66
  BC018391                           KRT25         Keratin 25                                             6.56
  BC116672                           KRT26         Keratin 26                                             7.78
  AB288231                           KRT28         Keratin 28                                             4.28
  BC117553                           KRT32         Keratin 32                                             6.04
  BC12542                            KRT34         Keratin 34                                             101.08
  BC100542                           KRT35         Keratin 35                                             6.86
  BC119521                           KRT40         Keratin 40                                             10.11
  BC125346                           KRT71         Keratin 71                                             2.90
  BC067067                           KRT73         Keratin 73                                             4.34
  BC107395                           KRT77         Keratin 77                                             9.12
  BC119366                           KRT80         Keratin 80                                             2.21
  AF312018                           KRT81         Keratin 81                                             30.65
  BC10897                            KRT82         Keratin 82                                             10.18
  BC152922                           KRT85         Keratin 85                                             19.46
  BC029257                           KRT33A        Keratin associated protein 33A                         39.26
  NM_013570                          KRT33B        Keratin associated protein 33B                         4.79
  NM_001085526                       KRTAP1-2      Keratin associated protein 1-3                         13.42
  XM_894811                          KRTAP3-1      Keratin associated protein 3-1                         29.03
  BC156698                           KRTAP4-2      Keratin associated protein 4-2                         19.09
  NM_026834                          KRTAP4-6      Keratin associated protein 4-6                         24.72
  BC115508                           KRTAP4-7      Keratin associated protein 4-7                         33.02
  NM_001085547                       KRTAP4-8      Keratin associated protein 4-8                         43.14
  NM_001085548                       KRTAP4-9      Keratin associated protein 4-9                         24.62
  BC016249                           KRTAP4-16     Keratin associated protein 4-16                        42.20
  NM_015809                          KRTAP5-4      Keratin associated protein 5-4                         19.54
  NM_027771                          KRTAP7-1      Keratin associated protein 7-1                         137.50
  AK133727                           KRTAP8-1      Keratin associated protein 8-1                         18.92
  BC116210                           KRTAP9-1      Keratin associated protein 9-1                         11.56
  BC156686                           KRTAP9-3      Keratin associated protein 9-3                         35.46
  NM_001085527                       KRTAP9-5      Keratin associated protein 9-5                         12.10
  BC116219                           KRTAP15       Keratin associated protein 15                          60.31
  BC116200                           KRTAP19-4     Keratin associated protein 19-4                        10.75
  BC115545                           KRTAP19-3     Keratin associated protein 19-3                        8.54
  BC132612                           KRTAP6-5      Keratin associated protein 6-5                         14.96
  BC132658                           KRTAP16-3     Keratin associated protein 16-3                        39.91
  BC128283                           KRTAP26-1     Keratin associated protein 26-1                        6.51
                                                                                                          
  **C, Lipid metabolic process**                                                                          
                                                                                                          
  GenBank accession no.              Gene name     Gene full name                                         Fold downregulation
                                                                                                          
  AK003689                           LYPLA2        Lysophospholipase II                                   2.00
  BC027524                           PLA2G2E       Phospholipase A2, group IIE                            2.60
  BC148434                           PLCH2         Phospholipase C eta 2                                  2.13
  BC047281                           AGPAT4        1-acylglycerol-3-phosphate O-acyltransferase 4         3.81
  BC031987                           AGPAT5        1-acylglycerol-3-phosphate O-acyltransferase 5         3.17
  AK019476                           SMPD3         Sphingomyelin Phosphodiesterase 3 neutral              2.15
  AK088962                           SMPD2         Sphingomyelin phosphodiesterase 2 neutral              2.10
  BC013751                           ALOX12E       Arachidonate lipoxygenase                              3.90
  BC043059                           LASS5/Cers5   Epidermal ceramide synthase 5                          2.82
  BC075627                           DGKK          Diacylglycerol kinase κ                                3.89
  BC021597                           APOM          Apolipoprotein M                                       2.58
  BC006863                           FAAH          Fatty acid amide hydrolase                             2.22
  BC071266                           FADS3         Fatty acid desaturase 3                                2.53
                                                                                                          
  **D, Gap junction**                                                                                     
                                                                                                          
  GenBank accession no.              Gene name     Gene full name                                         Fold downregulation
                                                                                                          
  AY427554                           GJA1          Gap junction protein α1                                2.00
  AY390399                           GJA3          Gap junction protein α3                                2.57
  BC024387                           GJB3          Gap junction protein β3                                2.77
                                                                                                          
  **E, Tight junction**                                                                                   
                                                                                                          
  GenBank accession no.              Gene name     Gene full name                                         Fold downregulation
                                                                                                          
  AK165750                           PRKCZ         Protein kinase C ζ                                     2.37
  DQ682659                           MARVELD2      MARVEL domain containing 2                             3.81
  AK190015                           TJAP1         Tight junction associated protein 1                    2.08
  BC049662                           MPP7          Membrane palmitoylated protein 7                       2.11
                                                                                                          
  **F, Desmosome**                                                                                        
                                                                                                          
  GenBank accession no.              Gene name     Gene full name                                         Fold downregulation
                                                                                                          
  BC020144                           DSG2          Desmoglein 2                                           4.48

###### 

Upregulation of epidermal barrier-associated genes following treatment with all-*trans* retinoic acid in the mouse skin (n=1 per group;-fold change \>2; P\<0.05).

  A, Cornified envelope components                                                                                               
  ------------------------------------------------ ----------------- ----------------------------------------------------------- -------------------
  BC115788                                         LCE3B             Late cornified envelope 3B                                  3.17
  BC119239                                         LCE3C             Late cornified envelope 3C                                  5.35
  BC125542                                         SPRR2J            Small proline-rich protein 2J                               2.38
  BC130233                                         SPRR2G            Small proline-rich protein 2G                               3.57
  BC078629                                         S100A8            S100 calcium binding protein A8 (calgranulin A)             3.31
  AK143826                                         S100A9            S100 calcium binding protein A9 (calgranulin B)             3.81
                                                                                                                                 
  **B, Serine protease and protease inhibitors**                                                                                 
                                                                                                                                 
  GenBank accession no.                            Gene name         Gene full name                                              Fold upregulation
                                                                                                                                 
  BC031119                                         KLK6              Kallikrein related-peptidase 6                              3.22
  BC002100                                         KLK10             Kallikrein related-peptidase 10                             2.90
  XM_893506                                        KLK12             Kallikrein related-peptidase 12                             2.50
  BC054091                                         SERPINE1          Serine (cysteine) proteinase inhibitor, clade E, member 1   2.15
  BC010675                                         SERPINE2          Serine (cysteine) proteinase inhibitor, clade E, member 2   2.98
                                                                                                                                 
  **C, Lipid metabolic process**                                                                                                 
                                                                                                                                 
  GenBank accession no.                            Gene name         Gene full name                                              Fold upregulation
                                                                                                                                 
  BC010829                                         ACNAT2            Acyl-coenzyme A amino acid N-acyltransferase 2              2.03
  DQ469311                                         ACNAT1            Acyl-coenzyme A amino acid N-acyltransferase 1              2.94
  AK171255                                         ACOT11            Acyl-CoA thioesterase 11                                    3.73
  BC050828                                         UGCG              UDP-glucose ceramide glucosyltransferase                    2.21
  BC060600                                         PLA2G4E           Phospholipase A2, group IVE                                 2.39
  BC003470                                         PLA1A             Phospholipase A1 member A                                   2.06
  BC003943                                         DPAGT1            Dolichyl-phosphate (UDP-N-acetylglucosamine) glycerol       2.10
                                                                                                                                 
  **D, Tight junction**                                                                                                          
                                                                                                                                 
  GenBank accession no.                            Gene name         Gene full name                                              Fold upregulation
                                                                                                                                 
  BC015252                                         CLDN2 Claudin-2   2.43                                                        
                                                                                                                                 
  **E, Transcriptional factors**                                                                                                 
                                                                                                                                 
  GenBank accession no.                            Gene name         Gene full name                                              Fold upregulation
                                                                                                                                 
  BC070398                                         PPARδ             Peroxisome proliferator activator receptor δ                2.00

###### 

Downregulation of epidermal barrier-associated genes following treatment with all-*trans* retinoic acid in HaCaT cells (n=1 per group;-fold change \>2; P\<0.05).

  A, Intermediate filament                                                                 
  ------------------------------------------ ----------- --------------------------------- ---------------------
  NM_181619                                  KRTAP21-1   Keratin associated protein 21-1   2.38
  NM_033448                                  KRT71       Keratin 71                        2.00
  BC024292                                   KRT5        Keratin 5                         2.22
                                                                                           
  **B, Proteases and protease inhibitors**                                                 
                                                                                           
  GenBank accession no.                      Gene name   Gene full name                    Fold downregulation
                                                                                           
  BC069417                                   SERPINB7    Serpin family B member 7          3.15
  NM_000185                                  SERPIND1    Serpin family D member 1          2.36
  NM_007173                                  PRSS23      Serine protease 23                4.13
  NM_022046                                  KLK14       Kallikrein related peptidase 10   2.29
                                                                                           
  **C, Tight junction**                                                                    
                                                                                           
  GenBank accession no.                      Gene name   Gene full name                    Fold downregulation
                                                                                           
  AK128686                                   PDZD2       PDZ domain containing 2           2.15

###### 

Upregulation of epidermal barrier-associated genes following treatment with all-*trans* retinoic acid in HaCaT cells (n=1 per group;-fold change \>2; P\<0.05).

  A, Intermediate filament                                                                                        
  ------------------------------------------ ----------------- -------------------------------------------------- -------------------
  NM_002275                                  KRT15             Keratin 15                                         2.07
  BC072018                                   KRT17             Keratin 17                                         2.68
  AB096945                                   KRTAP19-4         Keratin associated protein 19-4                    2.07
  BC101555                                   KRTAP7-1          Keratin associated protein 7-1 (gene/pseudogene)   2.05
  NM_032524                                  KRTAP4-4          Keratin associated protein 4-4                     2.16
                                                                                                                  
  **B, Proteases and protease inhibitors**                                                                        
                                                                                                                  
  GenBank accession no.                      Gene name         Gene full name                                     Fold upregulation
                                                                                                                  
  NM_001085                                  SERPINA3          Serpin family A member 3                           12.30
  NM_000624                                  SERPINA5          Serpin family A member 5                           2.03
  BC034528                                   SERPINB8          Serpin family B member 8                           2.11
  NM_000934                                  SERPINF2          Serpin family F member 2                           2.06
  NM_002575                                  SERPINB2          Serpin family B member 2                           2.17
  BC009726                                   PRSS22            Serine protease 22                                 4.26
  AF335478                                   KLK3              Kallikrein related peptidase 3                     2.27
  NM_001012964                               KLK6              Kallikrein related peptidase 6                     2.95
  NM_002776                                  KLK10             Kallikrein related peptidase 10                    2.44
  NM_006853                                  KLK11             Kallikrein related peptidase 11                    2.43
  NM_015596                                  KLK13             Kallikrein related peptidase 13                    2.80
  NM_017509                                  KLK15             Kallikrein related peptidase 15                    2.02
                                                                                                                  
  **C, Tight junction**                                                                                           
                                                                                                                  
  GenBank accession no.                      Gene name         Gene full name                                     Fold upregulation
                                                                                                                  
  BC029886                                   OCLN Occludin     2.63                                               
  NM_001305                                  CLDN4 Claudin-4   2.02                                               
